Schepens Eye Research Institute and Dept. of Ophthalmology, 20 Staniford Street, Harvard Medical School, Boston, MA 02114, USA.
Exp Eye Res. 2012 Feb;95(1):16-23. doi: 10.1016/j.exer.2011.08.014. Epub 2011 Aug 30.
The corneal endothelial monolayer helps maintain corneal transparency through its barrier and ionic "pump" functions. This transparency function can become compromised, resulting in a critical loss in endothelial cell density (ECD), corneal edema, bullous keratopathy, and loss of visual acuity. Although penetrating keratoplasty and various forms of endothelial keratoplasty are capable of restoring corneal clarity, they can also have complications requiring re-grafting or other treatments. With the increasing worldwide shortage of donor corneas to be used for keratoplasty, there is a greater need to find new therapies to restore corneal clarity that is lost due to endothelial dysfunction. As a result, researchers have been exploring alternative approaches that could result in the in vivo induction of transient corneal endothelial cell division or the in vitro expansion of healthy endothelial cells for corneal bioengineering as treatments to increase ECD and restore visual acuity. This review presents current information regarding the ability of human corneal endothelial cells (HCEC) to divide as a basis for the development of new therapies. Information will be presented on the positive and negative regulation of the cell cycle as background for the studies to be discussed. Results of studies exploring the proliferative capacity of HCEC will be presented and specific conditions that affect the ability of HCEC to divide will be discussed. Methods that have been tested to induce transient proliferation of HCEC will also be presented. This review will discuss the effect of donor age and endothelial topography on relative proliferative capacity of HCEC, as well as explore the role of nuclear oxidative DNA damage in decreasing the relative proliferative capacity of HCEC. Finally, potential new research directions will be discussed that could take advantage of and/or improve the proliferative capacity of these physiologically important cells in order to develop new treatments to restore corneal clarity.
角膜内皮单层通过其屏障和离子“泵”功能帮助维持角膜透明度。这种透明性功能可能会受到损害,导致内皮细胞密度(ECD)严重下降、角膜水肿、大泡性角膜病变和视力丧失。尽管穿透性角膜移植术和各种形式的内皮角膜移植术能够恢复角膜清晰度,但它们也可能会出现需要再次移植或其他治疗的并发症。由于全球可供用于角膜移植的供体角膜日益短缺,因此更需要找到新的治疗方法来恢复因内皮功能障碍而丧失的角膜清晰度。因此,研究人员一直在探索替代方法,这些方法可能导致角膜内皮细胞在体内短暂分裂,或在体外扩增健康的内皮细胞,用于角膜生物工程,以增加 ECD 并恢复视力。这篇综述介绍了人角膜内皮细胞(HCEC)分裂的能力,作为开发新疗法的基础。将介绍细胞周期的正调控和负调控,作为将要讨论的研究的背景信息。将介绍探索 HCEC 增殖能力的研究结果,并讨论影响 HCEC 分裂能力的具体条件。还将介绍已测试过的诱导 HCEC 短暂增殖的方法。这篇综述将讨论供体年龄和内皮拓扑对 HCEC 相对增殖能力的影响,并探讨核氧化 DNA 损伤在降低 HCEC 相对增殖能力中的作用。最后,将讨论潜在的新研究方向,这些方向可以利用和/或改善这些生理上重要细胞的增殖能力,以开发新的治疗方法来恢复角膜清晰度。